Lantern Pharma Q1 net loss narrows on R&D cost cuts

Lantern Pharma

15/05/2026 21:13

Overview

US oncology drug developer's Q1 net loss narrowed 27% yr/yr as R&D spend fell sharply

Company launched withZeta.ai AI platform commercially and advanced multiple clinical programs

Lantern strengthened balance sheet with up to $9.25 mln financing, plans withZeta.ai separation

Outlook

Company expects current liquidity to fund operations into mid-first qtr 2027

Lantern plans additional HARMONIC trial data readouts in second half 2026

Company to execute strategic separation of withZeta.ai platform assets in 2026

Result Drivers

R&D COST CUTS - Co said 47% yr/yr reduction in R&D spend was mainly due to lower research study, clinical trial material, and salary expenses

CLINICAL PROGRAM ADVANCEMENT - Co progressed multiple clinical programs, including regulatory milestones for LP-300 and STAR-001

AI PLATFORM LAUNCH - Commercial introduction of withZeta.ai, Lantern's multi-agentic AI co-scientist platform for rare and complex cancer drug development

Company press release: ID:nBw2XqkyBa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.30
Q1 Net Income
-$3.30 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lantern Pharma Inc is $25.00, about 698.7% above its May 14 closing price of $3.13

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)